[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-cancer-syndromes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-cancer-syndromes":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,84,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100622038","questionnaire-on-congenital-cancer-signs-through-self-assessment-100622038",false,"NCT07378423","Questionnaire on Congenital Cancer Signs Through Self-Assessment","Questionnaire on Congenital Cancer Signs Through Self-Assessment (QUOCCAS)","QUOCCAS","Inclusion Criteria:\n\n* The investigators will include newly diagnosed patients who received a cancer diagnosis included in the International Classification of Childhood Cancer version 3 (ICCC3) criteria, treated at participating hospitals\n\nExclusion Criteria:\n\n* Over 21 years of age","ALL","21 Years",{"count":20,"type":21},205,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical trial tests whether a patient- and caregiver-completed questionnaire (QUOCCAS) can accurately help identify children and adolescents with cancer who may have an underlying cancer predisposition syndrome (CPS). The study will also evaluate whether providing families with an educational brochure before their clinic visit improves their understanding of genetics and their satisfaction with care.\n\nThe main questions it aims to answer are:\n\n* Does QUOCCAS identify children at risk for CPS as accurately as physician-based tools and compared to genetic testing?\n* Does the Pre-Visit Preparation (PVP) brochure improve caregiver knowledge about genetics?\n* Does the PVP brochure improve caregiver satisfaction with the care and information they receive?\n\nParticipants will:\n\n* Complete the QUOCCAS questionnaire about family history, clinical features, and cancer signs\n* Provide a blood or saliva sample for genetic testing (whole-exome or whole-genome sequencing)\n* Randomly receive or not receive the educational Pre-Visit Preparation brochure before completing the questionnaire\n* Complete brief surveys on their knowledge and satisfaction",[27,28,29,30],"Cancer Predisposition Syndromes","Pediatric Cancer","Childhood Neoplasms","Hereditary Cancer Syndromes",[32,33,34,35,36,37,38,39,40],"Cancer Predisposition Syndrome (CPS)","Pediatric Oncology","Childhood Cancer","Genetic Testing","Whole-Exome Sequencing (WES)","Screening Tool","Patient-Reported Outcomes","Genetic Literacy","Whole-Genome Sequencing (WGS)","RECRUITING","2026-04-30",{"date":44,"type":45},"2026-05-01","ACTUAL",{"date":47,"type":45},"2026-04-01",{"date":49,"type":21},"2029-12-31",{"name":51,"class":52},"Insel Gruppe AG, University Hospital Bern","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":53},"100566383","closing-the-gaps-guideline-adherence-prevention-and-surveillance-in-hereditary-cancer-100566383","NCT06654466","Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer","Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing","Inclusion Criteria:\n\n* Ages 18-49 years, inclusive\n* previous cancer genetic testing with a finding of a pathogenic or likely pathogenic variant resulting in an increased risk of cancer warranting clinical management.\n* English-speaking and -reading\n* Receiving care at Dana Farber Cancer Institute\n* Not in active cancer therapy at the time of approach\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>49 years\n* Has not had genetic testing for hereditary cancer syndromes or has been tested but no pathogenic or likely pathogenic variant was identified.\n* Non-English speaking and reading\n* Not receiving care at Dana Farber Cancer Institute\n* Active cancer with therapy in progress","18 Years","49 Years",{"count":64,"type":21},100,[24],"The goal of this clinical trial is to see if a software platform can improve cancer screening in young adults with genetic risk for cancer.\n\nThe trial will also help improve the software platform (Nest). The main questions it aims to answer are:\n\n* Do Nest users know more about their cancer risks and recommended care than non-users?\n* Do Nest users have less psychological distress than non-users?\n* Do Nest users share cancer risks with family and other doctors more than non-users?\n* Are Nest users more likely than non-users to have up-to-date care plans?\n\nResearchers will compare Nest users to non-users to see if the Nest users are more likely to do recommended cancer screening.\n\nParticipants will:\n\n* Have a genetic counseling or follow up visit\n* Take a post-visit survey\n* Intervention arm only: use the Nest Patient Navigator\n* Complete screening and follow-up care recommended by doctors",[30,68],"Clinical Decision Support",[30,70,71,72,68,73],"Cancer Surveillance","Cancer Prevention","Guideline Adherence","Adolescent and Young Adult Cancer","2026-02-23",{"date":76,"type":45},"2026-02-25",{"date":78,"type":45},"2026-02-10",{"date":80,"type":21},"2027-09",{"name":82,"class":83},"Nest Genomics","INDUSTRY",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":92,"minAge":61,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100596960","trial-of-combined-obstetric-carrier-screening-and-hereditary-cancer-screening-100596960","NCT07052266","Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening","Feasibility of Obstetric and Cancer Universal Screening","FOCUS","Inclusion Criteria:\n\n* Age 18 years - 55 years\n* Pregnant patients receiving obstetrical-related care or receiving preconception\u002Ffertility care at a WCM-affiliated enrollment site.\n* Patients who have elected to undergo OCS with the WCM-affiliated obstetrics provider\n* Patients with prior OCS but planned to repeat OCS are eligible\n* Patients can speak and read in English or Spanish\n\nExclusion Criteria:\n\n* Patients who have previously completed a multigene hereditary cancer syndrome panel\n* Patients who have a hematologic cancer or hematologic pre-cancer\n* Patients who have a history of an autologous bone marrow transplant","FEMALE","55 Years",{"count":95,"type":21},550,[24],"The investigators hypothesize that pregnancy and preconception care may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal or preconception\u002Ffertility care. The goal is to evaluate the acceptability of BRCA1\u002F2 testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention and be cost-effective, especially among underserved populations.",[30],[35,100,101,102,103,104],"Carrier Screening","Prenatal Screening","Reproductive Genetic Testing","Feasibility Study","Universal Screening","2025-12-18",{"date":107,"type":45},"2025-12-26",{"date":109,"type":45},"2025-09-02",{"date":111,"type":21},"2028-12",{"name":113,"class":52},"Weill Medical College of Cornell University",5,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":122,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":123,"targetDuration":125,"studyType":126,"phases":4,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":53},"100523515","discovering-new-targets-for-colorectal-and-endometrial-cancer-risk-reduction-100523515","NCT06096688","Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction","Discovering New Targets for Hereditary and Sporadic Colorectal and Endometrial Cancer Risk Reduction","The following eligibility criteria must be met as follows:\n\n1. Age ≥ 18 years old.\n2. One of the following must be met:\n\n   1. Diagnosis of a Hereditary Cancer Syndrome by positive genetic testing and\u002For clinical criteria to undergo an endoscopy procedure (esophagoduodenoscopy and\u002For colonoscopy\u002Fflexible sigmoidoscopy), or endometrial screening procedure (transvaginal ultrasound and\u002For hysteroscopy and\u002For endometrial biopsy), OR\n   2. Individuals coming to Weill-Cornell Medicine\u002FNYPH to undergo an endoscopy procedure, transvaginal ultrasound, or hysteroscopy for average-risk (population-based) recommendation OR\n   3. Individuals diagnosed with colorectal cancer or endometrial cancer coming to Weill- Cornell Medicine\u002FNYPH for surgical treatment OR\n   4. Individuals coming to Weill-Cornell Medicine\u002FNYPH for care such as, but not limited to, diagnostic testing, clinic and\u002For treatment visit.\n3. Willingness and ability to sign informed consent.\n4. Ability to read\u002Funderstand English, Spanish, and\u002For simplified Chinese.",true,{"count":124,"type":21},1120,"1 Year","OBSERVATIONAL","The primary aim of this study is to collect and store data, tissue, and personal and family histories from patients being screened for colorectal cancer and\u002For endometrial cancer at NYPH and WCM for routine clinical care and to make these available for future use for molecular and mechanistic studies.",[129,130,30],"Colorectal Cancer","Endometrial Cancer",[132,133,134,135,30,136,137,138,139],"personal and family history","genomic\u002Fepigenetic","polyps","carcinomas","mucosa","blood serum markers","chemoprevention","registry","2025-08-26",{"date":142,"type":45},"2025-09-04",{"date":144,"type":45},"2019-05-29",{"date":146,"type":21},"2026-12-31",{"name":113,"class":52}]